SG11201807979SA - Palatable compositions including sodium phenylbutyrate and uses thereof - Google Patents

Palatable compositions including sodium phenylbutyrate and uses thereof

Info

Publication number
SG11201807979SA
SG11201807979SA SG11201807979SA SG11201807979SA SG11201807979SA SG 11201807979S A SG11201807979S A SG 11201807979SA SG 11201807979S A SG11201807979S A SG 11201807979SA SG 11201807979S A SG11201807979S A SG 11201807979SA SG 11201807979S A SG11201807979S A SG 11201807979SA
Authority
SG
Singapore
Prior art keywords
international
bend
pct
including sodium
compositions including
Prior art date
Application number
SG11201807979SA
Inventor
Leah E Appel
Joshua R Shockey
D Christopher Schelling
Original Assignee
Acer Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acer Therapeutics Inc filed Critical Acer Therapeutics Inc
Publication of SG11201807979SA publication Critical patent/SG11201807979SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11111111111111011101010111110101111101110111100111110111111111111111111111110111111 International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... .....1 WO 2017/160345 Al 21 September 2017 (21.09.2017) WIP0 I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 31/192 (2006.01) A61K 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2016/057415 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: 17 October 2016 (17.10.2016) KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/308,614 15 March 2016 (15.03.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: ACER THERAPEUTICS INC. [US/US]; 222 Third Street, Suite 2240, Cambridge, MA 02142 (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors; and TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, — (71) Applicants : APPEL, Leah, E. [US/US]; 4051 NW Northcliff Dr., Bend, OR 97703 (US). SHOCKEY, Josh- oua, R. [US/US]; 63591 OB Riley, Bend, OR 97703 (US). SCHELLING, D. Christopher [US/US]; 19171 Park DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). — _ Commons Drive, Bend, OR 97703 (US). Published: Agent: BIEKER-BRADY, Kristina; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US). (74) — with international search report (Art. 21(3)) _ = = = = = = = = 1-1 11 in ii- en © ,tD 1-1 IN 1-1 C:::: ) (54) Title: PALATABLE COMPOSITIONS INCLUDING SODIUM PHENYLBUTYRATE AND USES THEREOF ei r ... ) (57) : The present invention features palatable pharmaceutical compositions including sodium phenylbutyrate and methods '° for the treatment of inborn errors of metabolism (e.g., Maple Syrup Urine Disease or Urea Cycle Disorders), neurodegenerative dis - .,- orders such as Parkinson's disease, spinal muscular atrophy, dystonia, or inclusion-body myositis with such compositions.
SG11201807979SA 2016-03-15 2016-10-17 Palatable compositions including sodium phenylbutyrate and uses thereof SG11201807979SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662308614P 2016-03-15 2016-03-15
PCT/US2016/057415 WO2017160345A1 (en) 2016-03-15 2016-10-17 Palatable compositions including sodium phenylbutyrate and uses thereof

Publications (1)

Publication Number Publication Date
SG11201807979SA true SG11201807979SA (en) 2018-10-30

Family

ID=59847918

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807979SA SG11201807979SA (en) 2016-03-15 2016-10-17 Palatable compositions including sodium phenylbutyrate and uses thereof

Country Status (21)

Country Link
US (5) US20170266115A1 (en)
EP (2) EP4104822A1 (en)
JP (2) JP7136763B2 (en)
KR (1) KR20190008840A (en)
AU (1) AU2016398029B2 (en)
BR (1) BR112018068665B1 (en)
CA (1) CA3017573A1 (en)
DK (1) DK3429559T3 (en)
ES (1) ES2922749T3 (en)
HR (1) HRP20220856T1 (en)
HU (1) HUE059630T2 (en)
IL (2) IL296490A (en)
LT (1) LT3429559T (en)
MX (2) MX2018011229A (en)
PL (1) PL3429559T3 (en)
PT (1) PT3429559T (en)
RS (1) RS63383B1 (en)
SA (1) SA518400020B1 (en)
SG (1) SG11201807979SA (en)
SI (1) SI3429559T1 (en)
WO (1) WO2017160345A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017160345A1 (en) 2016-03-15 2017-09-21 Acer Therapeutics Inc. Palatable compositions including sodium phenylbutyrate and uses thereof
CA3184989A1 (en) * 2020-07-07 2022-01-13 Christopher D. Schelling Methods of administering taste masked phenylbutyrate and compositions therefor
CN113332267A (en) * 2021-03-31 2021-09-03 中山大学孙逸仙纪念医院 Application of sodium phenylbutyrate in preparation of medicine for preventing or treating Parkinson's disease
IT202100019613A1 (en) 2021-07-23 2023-01-23 Kolfarma S R L Pharmaceutical or dietary supplement formulation containing alpha-lactalbumin and butyric acid or a salt thereof
CN216570857U (en) * 2021-08-11 2022-05-24 Acer治疗公司 Dosage form and plurality of dosage forms for improving palatability of drug substances

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
AR034813A1 (en) 2001-07-20 2004-03-17 Novartis Ag PHARMACEUTICAL COMPOSITIONS AND USE OF THE SAME
EP1291015A1 (en) 2001-09-10 2003-03-12 Lunamed AG Dosage forms having prolonged active ingredient release
US20040152784A1 (en) * 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
FR2850275B1 (en) 2003-01-24 2005-04-08 Scherer Technologies Inc R P SOFT MACHINE CAPSULES CONTAINING AN ACTIVE ACTIVE SUBSTANCE WITH MASK TASTE
JP2005060310A (en) 2003-08-13 2005-03-10 Towa Yakuhin Kk Preparation for oral administration with masked unpleasant taste
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
ATE378042T1 (en) * 2004-04-12 2007-11-15 Pfizer Prod Inc DRUGS WITH DISCOVERED TASTE IN BRUSHING MULTIPARTICLES
US8821928B2 (en) * 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
ES2332687B1 (en) 2008-03-13 2011-01-10 Proyecto De Biomedicina Cima, S.L. NEW USES OF 4PBA AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS.
US20100136110A1 (en) * 2008-09-30 2010-06-03 Astellas Pharma Inc. Granular pharmaceutical composition for oral administration
ES2546526T3 (en) 2009-07-24 2015-09-24 Baylor College Of Medicine Methods of modulation of branched chain acids and their uses
FR2959129B1 (en) * 2010-04-21 2013-02-01 Lucane Pharma PARTICLES COMPRISING SODIUM 4-PHENYLBUTYRATE, PREPARATION METHOD AND USES
EP2389932A1 (en) * 2010-05-28 2011-11-30 Lunamed AG Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts
US20130323362A1 (en) 2010-12-06 2013-12-05 Degama Berrier Ltd. Composition and method for improving stability and extending shelf life of probiotic bacteria and food products thereof
EP2709593A4 (en) * 2011-05-16 2014-10-29 Sun Pharma Advanced Res Co Ltd Multi-particulate pharmaceutical composition
JP2012240917A (en) 2011-05-16 2012-12-10 Zensei Yakuhin Kogyo Kk Fine particle for preparation and medication containing the same
AU2012265842A1 (en) 2011-06-07 2014-01-23 SPAI Group Ltd. Compositions and methods for improving stability and extending shelf life of sensitive food additives and food products thereof
RU2014100048A (en) * 2011-06-22 2015-07-27 Гмп-Орфан 4-Phenylbiturate Salt Intended for the Treatment of Motor Neurons or Metabolic Diseases during Rectal Administration
AU2012296925A1 (en) 2011-08-12 2014-02-06 Boehringer Ingelheim Vetmedica Gmbh Taste masked pharmaceutical composition
EP2599477A1 (en) * 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbutyric acid sustained release formulation
US8993041B2 (en) 2012-10-15 2015-03-31 New Jersey Institute Of Technology Taste masked active pharmaceutical powder compositions and processes for making them
CN110302168A (en) 2013-01-28 2019-10-08 万平 Position quick-release bioadhesive polymer and its preparation method and application
JP6147711B2 (en) 2014-05-26 2017-06-14 富士フイルム株式会社 Pharmaceutical composition and method for producing the same, orally disintegrating tablet and method for producing the same
WO2017160345A1 (en) 2016-03-15 2017-09-21 Acer Therapeutics Inc. Palatable compositions including sodium phenylbutyrate and uses thereof

Also Published As

Publication number Publication date
US11202767B2 (en) 2021-12-21
BR112018068665B1 (en) 2023-12-26
LT3429559T (en) 2022-08-10
HUE059630T2 (en) 2022-11-28
IL261777B (en) 2022-10-01
WO2017160345A1 (en) 2017-09-21
MX2022003969A (en) 2022-04-25
CA3017573A1 (en) 2017-09-21
IL261777B2 (en) 2023-02-01
ES2922749T3 (en) 2022-09-20
EP4104822A1 (en) 2022-12-21
SI3429559T1 (en) 2022-11-30
PT3429559T (en) 2022-07-20
RS63383B1 (en) 2022-08-31
IL261777A (en) 2018-10-31
US20230133629A1 (en) 2023-05-04
BR112018068665A2 (en) 2019-02-05
WO2017160345A8 (en) 2018-02-22
JP2019509345A (en) 2019-04-04
US11433041B2 (en) 2022-09-06
MX2018011229A (en) 2019-05-30
US11154521B2 (en) 2021-10-26
IL296490A (en) 2022-11-01
AU2016398029B2 (en) 2023-03-02
JP7136763B2 (en) 2022-09-13
US20210220304A1 (en) 2021-07-22
EP3429559A4 (en) 2019-11-06
US20210186908A1 (en) 2021-06-24
KR20190008840A (en) 2019-01-25
AU2016398029A1 (en) 2018-10-11
JP2022106927A (en) 2022-07-20
EP3429559B1 (en) 2022-04-13
EP3429559A1 (en) 2019-01-23
US20170266115A1 (en) 2017-09-21
US20200261385A1 (en) 2020-08-20
HRP20220856T1 (en) 2022-10-14
PL3429559T3 (en) 2022-11-07
DK3429559T3 (en) 2022-07-11
SA518400020B1 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
SG11201809082WA (en) Nlrp3 modulators
SG11201807979SA (en) Palatable compositions including sodium phenylbutyrate and uses thereof
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201805940QA (en) Benzopyrazole compounds and analogues thereof
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201408174UA (en) Antibody formulation
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201808192RA (en) Non-invasive diagnostic of non-alcoholic steatohepatitis
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201808830YA (en) Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201807597UA (en) Methods of treating depression using orexin-2 receptor antagonists